TNYA

Over the past six months, Tenaya Therapeutics' stock price experienced a significant decline of 67.20% from October 6, 2025, to October 5, 2026. Since June 30, 2026, the stock lost approximately 25% due to a significant miss on its fiscal Q2 2026 earnings and revenue, higher-than-anticipated operating expenses, a notable non-cash impairment charge of $21.8 million, and a $1.4 million loss on lease termination. On August 5, 2026, the company reported its Q2 2026 financial results, missing revenue estimates and reporting a Q1 loss. In September 2026, Tenaya Therapeutics announced the appointment of Eric Hyllengren as Chief Financial Officer. On September 14, 2026, the company was granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401, supported by positive interim data from the RIDGE™-1 Phase 1b/2 clinical trial, which was associated with a +7.95% stock movement. The company participated in several investor conferences in September and August 2026, outlining its pipeline and discussing the need for more capital. In May 2026, interim data from the RIDGE-1 Phase 1b/2 clinical trial for TN-401 showed reductions in premature ventricular contractions in all six patients, and the treatment was generally well tolerated.